[Study progress of tyrosine kinase inhibitor discontinuation in children with chronic myeloid leukemia].
作者信息
Zheng F Y, Wang M, Zhang L P, Jiang Q
机构信息
Department of Pediatrics, Peking University People's Hospital, Beijing 100044, China.
Department of Hematology, Peking University People's Hospital, Peking University Institute of Hematology, Beijing 100044, China.
出版信息
Zhonghua Xue Ye Xue Za Zhi. 2023 Feb 14;44(2):174-176. doi: 10.3760/cma.j.issn.0253-2727.2023.02.019.
Abstract
摘要
相似文献
1
[Study progress of tyrosine kinase inhibitor discontinuation in children with chronic myeloid leukemia].
Zhonghua Xue Ye Xue Za Zhi. 2023 Feb 14;44(2):174-176. doi: 10.3760/cma.j.issn.0253-2727.2023.02.019.
2
Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF.
Leukemia. 2024 Apr;38(4):893-897. doi: 10.1038/s41375-024-02215-9. Epub 2024 Mar 12.
3
Predictive value of early molecular response to tyrosine kinase inhibitors in pediatric patients with chronic myeloid leukemia.
Leuk Lymphoma. 2024 Jul;65(7):1024-1027. doi: 10.1080/10428194.2024.2331625. Epub 2024 Mar 21.
4
Prediction of sustained remission after tyrosine kinase inhibitor discontinuation with BCR::ABL1 digital PCR in chronic myeloid leukemia patients.
Eur J Haematol. 2024 Nov;113(5):606-613. doi: 10.1111/ejh.14271. Epub 2024 Jul 12.
5
Emergence of secondary fusions in chronic myeloid leukemia as a driver of tyrosine kinase inhibitor resistance and blast crisis transformation.
Leuk Res. 2024 Feb;137:107439. doi: 10.1016/j.leukres.2024.107439. Epub 2024 Jan 23.
6
Novel tyrosine kinase inhibitors in chronic myelogenous leukemia.
Curr Opin Oncol. 2006 Nov;18(6):578-83. doi: 10.1097/01.cco.0000245314.97638.d3.
7
Kinetics of molecular recurrence after tyrosine kinase inhibitor cessation in chronic phase chronic myelogenous leukaemia patients.
Br J Haematol. 2024 Apr;204(4):1536-1539. doi: 10.1111/bjh.19330. Epub 2024 Feb 7.
8
[Discontinuation of tyrosine kinase inhibitors before epiphyseal closure leading to improved short stature in pediatric chronic myelogenous leukemia].
Rinsho Ketsueki. 2024;65(3):175-179. doi: 10.11406/rinketsu.65.175.
9
BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
J Oncol Pharm Pract. 2018 Sep;24(6):433-452. doi: 10.1177/1078155217710553. Epub 2017 Jun 4.
10
De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tyrosine kinase inhibitors.
Am J Hematol. 2024 Apr;99(4):763-766. doi: 10.1002/ajh.27229. Epub 2024 Feb 5.
本文引用的文献
1
Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring.
Am J Hematol. 2022 Sep;97(9):1236-1256. doi: 10.1002/ajh.26642. Epub 2022 Jul 6.
2
Health-related quality of life in children with chronic myeloid leukemia in the chronic phase.
J Cancer Res Clin Oncol. 2022 Feb;148(2):341-350. doi: 10.1007/s00432-021-03832-y. Epub 2021 Oct 29.
3
Treatment-Free Remission in Chronic Myeloid Leukemia: Can We Identify Prognostic Factors?
Cancers (Basel). 2021 Aug 19;13(16):4175. doi: 10.3390/cancers13164175.
4
Discontinuation of Imatinib in Children with Chronic Myeloid Leukemia: A Study from the International Registry of Childhood CML.
Cancers (Basel). 2021 Aug 15;13(16):4102. doi: 10.3390/cancers13164102.
5
Chronic Myelogenous Leukemia in Childhood.
Curr Oncol Rep. 2021 Mar 14;23(4):40. doi: 10.1007/s11912-021-01025-x.
6
Definition, Epidemiology, Pathophysiology, and Essential Criteria for Diagnosis of Pediatric Chronic Myeloid Leukemia.
Cancers (Basel). 2021 Feb 14;13(4):798. doi: 10.3390/cancers13040798.
7
Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw. 2020 Oct 1;18(10):1385-1415. doi: 10.6004/jnccn.2020.0047.
8
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.
Leukemia. 2020 Apr;34(4):966-984. doi: 10.1038/s41375-020-0776-2. Epub 2020 Mar 3.
9
Results and outcome of intermittent imatinib (ON/OFF schedule) in children and adolescents with chronic myeloid leukaemia.
Br J Haematol. 2020 Mar;188(6):e101-e105. doi: 10.1111/bjh.16388. Epub 2020 Feb 22.
10
Risk of molecular recurrence after tyrosine kinase inhibitor discontinuation in chronic myeloid leukaemia patients: a systematic review of literature with a meta-analysis of studies over the last ten years.
Br J Haematol. 2020 May;189(3):452-468. doi: 10.1111/bjh.16408. Epub 2020 Feb 19.
Zotero 插件